Earnings Releases·Nov 5, 2026, 5:29 PM ET

Revelation Biosciences, Inc. — Three and Nine Months Ended September 30, 2026 Earnings Summary

Net loss widened to $3.3 million ($5.92 per share) for the three months ended September 30, 2026, compared to $1.9 million ($49.51 per share) in 2025, driven by a 74% increase in total operating expenses to $3.38 million.
Cash and cash equivalents declined to $9.1 million as of September 30, 2026, from $10.7 million at year-end 2025, with management projecting these funds are sufficient to sustain operations through the second quarter of 2027.
The company selected a global CRO to conduct the upcoming Phase 1 study for its lead candidate, Gemini, in patients with acute kidney injury, following a market assessment identifying a potential $94 billion total addressable market.
Significant capital structure changes occurred, with issued and outstanding common shares increasing to 683,442 from 226,330 at December 31, 2025, while total stockholders' equity decreased to $7.23 million.